Candida albicans Infection Models

Candida albicans (C. albicans) is a dimorphic yeast and the most common cause of invasive candidiasis. It lives as a harmless commensal in the gastrointestinal and genitourinary tracts and on the skin and mucous membranes of most healthy people. But when the balance shifts – through antibiotics, indwelling devices, abdominal surgery, immunosuppression, or critical illness – it overgrows and invades, producing the disease spectrum known as candidiasis. This can lead to infections ranging from common mucosal infection (oral and esophageal thrush, vulvovaginal candidiasis) to the far more dangerous invasive forms: candidemia and disseminated organ infection, intra-abdominal candidiasis, and device-associated disease.

Candida is among the leading causes of healthcare-associated bloodstream infection, and invasive candidiasis carries high mortality even when treated. Two traits drive its pathogenicity: the ability to switch reversibly between yeast and filamentous (hyphal and pseudohyphal) forms, which supports tissue invasion and dissemination, and the formation of biofilm on catheters, prosthetic surfaces, and mucosa. The WHO placed C. albicans in the critical-priority group of its 2022 Fungal Priority Pathogens List, and the CDC counts drug-resistant Candida species among the serious threats in its 2019 Antibiotic Resistance Threats Report. 

TransPharm Preclinical Solutions evaluates candidates against C. albicans in vivo across systemic, intra-abdominal, and skin infection models and produces the quantitative burden and survival data an antifungal program needs.

The scientific problem in a C. albicans study is matching the challenge to the question. The organism’s clinical range spans superficial mucocutaneous infection and life-threatening invasive disease, so the model and the infection site have to be chosen deliberately. A systemic challenge, an intra-abdominal challenge, and a skin challenge, for example, each answer a different development question. 

Host status is a second variable. Unlike some molds, C. albicans is virulent enough to establish lethal disseminated infection in an immunocompetent animal, while immunosuppressed models are also used to reproduce the neutropenic, at-risk patient. This choice shapes how a candidate should be read. 

Strain choice is the third: a susceptible reference isolate and an azole- or echinocandin-resistant clinical isolate answer different questions, particularly for a candidate positioned against resistant disease. TransPharm Preclinical Solutions maintains an on-site library of hundreds of validated pathogens and can source or validate characterized C. albicans isolates, including defined resistant phenotypes, to a program’s specifications.

Every study parameter – challenge strain, host species and strain, immune status, route of administration, comparator agents, and dosing schedule – is configurable to the scientific question. Core readouts are quantitative fungal burden (CFU/g or CFU/mL) in target tissues, organs, and blood, with survival and mortality tracking where applicable.

The following are available as add-ons to any study:

• Pharmacokinetic profiling and PK/PD analysis
• Blood chemistry
• Additional tissue harvests
• Histopathology

Fungemia – fungi in normally sterile blood – is the presentation that typically makes C. albicans dangerous. Candidemia can seed the heart, eyes, and deep organs, and it carries a high mortality rate. Unlike the angioinvasive molds, C. albicans is a frequent, culture-positive cause of true bloodstream infection, which makes this the central model for systemic antifungal activity. Animals are challenged by intravenous injection in the lateral tail vein. Test article may be administered by oral gavage or by subcutaneous, intravenous, or intraperitoneal injection. Endpoints include survival (mortality tracking) and fungal burden in harvested organs and/or blood. Validated in mice, with rats available on request. Validated C. albicans isolate: SC5314.

Intra-abdominal candidiasis – Candida peritonitis following perforation, surgery, or peritoneal dialysis – is a serious form of invasive disease. The peritonitis model supports both survival- and burden-based readouts and is a practical screen for activity against a rapidly progressive intra-abdominal infection. Animals are challenged by intraperitoneal injection, often with gastric mucin to help establish infection. Test article may be administered by oral gavage or by subcutaneous, intravenous, or intraperitoneal injection. Endpoints include mortality tracking and fungal burden in harvested organs and/or blood. Validated in mice and rats. Validated C. albicans isolate: SC5314.

Cutaneous and mucocutaneous candidiasis sit at the superficial end of the disease range, and the tape-stripping model reproduces superficial skin infection: surgical tape is repeatedly applied to and removed from a shaved area on the back to disrupt the epidermal barrier, after which the site is challenged topically. It is the appropriate model for topical agents and for early skin indications. The primary endpoint is quantitative fungal burden in the harvested skin. Validated in mice. Validated C. albicans isolate: SC5314.

The deep-wound model addresses the full-thickness end of the skin-infection range: a 6 mm biopsy punch creates a full-thickness wound over the thoracic spine on the dorsal surface, which is then inoculated in the wound bed, with quantitative fungal burden (CFU) in the harvested wound skin as the endpoint. Test article may be administered topically or by oral gavage or subcutaneous, intraperitoneal, or intravenous injection. Validated in mice, with rats available on request.

In vitro antifungal susceptibility testing complements the in vivo models. For a yeast, the reference method is broth microdilution MIC (CLSI M27), which can be paired with time-kill and checkerboard analysis to characterize a candidate and its combinations – useful for positioning against azole- or echinocandin-resistant isolates.

C. albicans remains more susceptible than several of its non-albicans relatives, and echinocandins are first-line for invasive candidiasis with the triazoles (notably fluconazole) also widely used – but resistance is emerging through well-defined routes, and it narrows an antifungal arsenal that already spans only a few classes. 

Azole resistance arises chiefly from two mechanisms: point mutations in ERG11, which encodes the azole target (lanosterol 14-α-demethylase) and reduce drug binding, and overexpression of efflux pumps – the ABC transporters Cdr1 and Cdr2 and the major-facilitator pump Mdr1 – which lowers intracellular drug levels and produces cross-resistance across the azole class. Echinocandin resistance is driven by hotspot mutations in FKS1, which encodes the (1,3)-β-D-glucan synthase target. Because these mechanisms differ in which drugs they compromise, the resistance profile of the challenge strain determines what an efficacy study can show.